Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e000331corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
by: Vidhya Karivedu, et al.
Published: (2019-01-01)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
by: Vidhya Karivedu, et al.
Published: (2019-01-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
by: Jung Sun Kim, et al.
Published: (2025-06-01)

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)

Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
by: Patrick Schummer, et al.
Published: (2023-01-01)

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
by: Jiajia Chen, et al.
Published: (2025-12-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
by: K. Kisielewska, et al.
Published: (2024-01-01)

Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
by: Shanshan Xu, et al.
Published: (2025-07-01)

Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma
by: Xiaofan Lu, et al.
Published: (2025-05-01)

Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
by: Sam Plessers, et al.
Published: (2025-01-01)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
by: Alessio Cortellini, et al.
Published: (2018-01-01)

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma
by: Lindsey Teal, et al.
Published: (2021-01-01)

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
by: Joan R. Choo, et al.
Published: (2025-06-01)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
by: Keisuke Funajima, et al.
Published: (2023-07-01)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
by: Narayanan Sadagopan, et al.
Published: (2019-01-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
by: Drew M Pardoll, et al.
Published: (2020-10-01)

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
by: Yoshihiko Tasaki, et al.
Published: (2025-01-01)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
by: Ian M. Bouligny, et al.
Published: (2025-02-01)

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
by: Romualdo Barroso-Sousa, et al.
Published: (2025-05-01)

Transarterial chemoembolization for patients with metastatic uveal melanoma in the liver
by: B. I. Dolgushin, et al.
Published: (2016-09-01)

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
by: Bowen Dai, et al.
Published: (2025-01-01)

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab
by: Hifaa Al Remawi, et al.
Published: (2025-12-01)

Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma
by: Umal Azmat, et al.
Published: (2016-01-01)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022-07-01)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
by: Caitlyn N. Myrdal, et al.
Published: (2020-01-01)

Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study
by: Toshiyuki Sumi, et al.
Published: (2025-01-01)

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
by: Lucille Vitek, et al.
Published: (2024-12-01)

Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations
by: Celeste Vallejo, et al.
Published: (2025-03-01)

The role of PET/CT in the diagnosis of metastatic uveal melanoma
by: S. V. Saakyan, et al.
Published: (2018-10-01)

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
by: Tanja D de Gruijl, et al.
Published: (2024-09-01)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
by: Carola Berking, et al.
Published: (2020-05-01)

Factors associated with time until metastatic spread in patients with primary uveal melanoma: A retrospective analysis.
by: Reinhard Told, et al.
Published: (2025-01-01)

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
by: Julie Williamson, et al.
Published: (2025-02-01)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
by: Jin Yao, et al.
Published: (2022-03-01)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
by: Christelle de La Fouchardière, et al.
Published: (2020-10-01)

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
by: Pavlos Msaouel, et al.
Published: (2025-01-01)

Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.
by: Dagmar von Bubnoff, et al.
Published: (2025-01-01)

Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)

Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab
by: M. Oshima, et al.
Published: (2025-03-01)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Similar Items

Similar Items